1. Scrip
  2. >>Business

Aurobindo-Sandoz End $1bn US Deal

Trade Clearance Not Forthcoming

 
• By Anju Ghangurde

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Footsteps_Arrows
Sandoz, Aurobindo Go Separate Ways • Source: Shutterstock

Aurobindo Pharma Ltd. and Novartis AG have called off their 2018 deal under which the Indian firm had snapped up Sandoz International GMBH’s US generic oral solids and dermatology businesses in a transaction worth around $1bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.